Még nem toboroz
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· 3. fázis· Nationwide Children's Hospital· Forrás
Még nem toboroz
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
2024-517295-37-00· 3. fázis· University Of Cologne· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial
2024-516544-26-00· 2. fázis· Universitaetsklinikum Heidelberg AöR· Forrás
Toboroz
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
2022-500676-59-00· 2. fázis· GPOH gGmbH· Forrás
Toboroz
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
NCT05293080· 3. fázis· Universitätsklinikum Hamburg-Eppendorf· Forrás
Toboroz
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307· 2. fázis· Universität Münster· Forrás
Toboroz
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037· 3. fázis· AstraZeneca· Forrás
Toboroz
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
NCT07246863· 2. fázis· CatalYm GmbH· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· 3. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· 3. fázis· Universitaetsklinikum Heidelberg AöR· Forrás
Toboroz
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT06134492· 3. fázis· Jena University Hospital· Forrás
Toboroz
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS
2024-512320-11-00· 3. fázis· Medical Center - University Of Freiburg· Forrás
Toboroz
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· 2. fázis· Goethe University· Forrás
Fut, nem toboroz
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795· 3. fázis· Day One Biopharmaceuticals, Inc.· Forrás
Toboroz
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· 3. fázis· The University Of Birmingham· Forrás
Fut, nem toboroz
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and total drug dose in comparison to the standard induction therapy and both treatments followed by a high dose therapy with autologous stem cell transplantation. The therapy is for patients with newly diagnosed primary lymphoma of the central nervous system.
NCT04931368· 3. fázis· Klinikum Der Landeshauptstadt Stuttgart gKAöR· Forrás
Toboroz
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· 3. fázis· Mats Heyman· Forrás
Toboroz
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
SIOP RANDOMET 2017
2023-508926-91-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Toboroz
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· 3. fázis· University Hospital Muenster· Forrás
Fut, nem toboroz
Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours
2023-507582-25-00· 3. fázis· Rheinische Friedrich-Wilhelms-Universitaet Bonn· Forrás
Fut, nem toboroz
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
NCT03948035· 3. fázis· Wuerzburg University Hospital· Forrás
Toboroz
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171· 2. fázis· Charite University, Berlin, Germany· Forrás
Fut, nem toboroz
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
NCT03206671· 3. fázis· University Hospital Muenster· Forrás
Toboroz
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
NCT02265770· 2/3. fázis· Centre Leon Berard· Forrás
Fut, nem toboroz
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· 2/3. fázis· Universitätsklinikum Hamburg-Eppendorf· Forrás